The Molecular Basis of Thrombin Allostery Revealed by a 1.8 Å Structure of the “Slow” Form  by Huntington, James A. & Esmon, Charles T.
Structure, Vol. 11, 469–479, April, 2003, 2003 Elsevier Science Ltd. All rights reserved. DOI 10.1016/S0969-2126(03)00049-2
The Molecular Basis of Thrombin Allostery
Revealed by a 1.8 A˚ Structure of the “Slow” Form
anticoagulant protein C in a reaction that requires throm-
bin binding to the endothelial cell receptor, thrombo-
modulin (TM) [2]. Thrombin binding to TM not only in-
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Cambridge Institute for Medical Research creases the rate of protein C activation, but also blocks
the ability of thrombin to cleave fibrinogen and to acti-Wellcome Trust/MRC Building
Hills Road vate platelets. The effects of TM binding on the activity
of thrombin are mediated, at least in part, by competitionCambridge CB2 2XY
United Kingdom for binding to anion binding exosite I of thrombin [3–5].
Activated protein C limits further thrombin formation by2 Cardiovascular Biology Research Program
Oklahoma Medical Research Foundation inactivating factors Va and VIIIa, two critical cofactors of
thrombin formation [6]. The ability of thrombin to switchDepartments of Pathology and Biochemistry and
Molecular Biology from procoagulant to anticoagulant, known as the
thrombin paradox [7], is a subject of great interest.Howard Hughes Medical Institute
University of Oklahoma Health Sciences Center It has been suggested that thrombin specificity is de-
termined, in part, by an allosteric switch caused by co-Oklahoma City, Oklahoma 73104
factor binding to exosites I and II or by substrate binding
[8, 9]. Support for this proposal comes from altered rates
of cleavage of peptide and protein substrates, changesSummary
in fluorescence, and the altered proteolytic susceptibil-
ity of the  loop at the entrance to the active site (for aThrombin participates in its own positive and negative
feedback loops, and its allosteric state helps deter- summary see [10]). Similar changes in properties have
also been observed in response to sodium ion bindingmine the hemostatic balance. Here we present the
1.8 A˚ crystallographic structure of S195A thrombin in (for a summary see [11]). At room temperature, thrombin
binds sodium with an apparent Kd of 20 mM, belowtwo conformational states: active site occupied and
active site free. The active site-occupied form shows which it is predominantly in a “slow” form and above
which it behaves as though bound to exosite I or IIhow thrombin can accommodate substrates, such as
protein C. The active site-free form is in a previously binding cofactors and adopts the so-called “fast” form.
Although over 100 structures of thrombin have beenunobserved closed conformation of thrombin, which
satisfies all the conditions of the so-called “slow” form. deposited in the Protein Data Bank, there is currently
no structural explanation for the unique ability of throm-A mechanism of allostery is revealed, which relies on
the concerted movement of the disulphide bond be- bin to undergo the allosteric transition from a slow to a
fast form. Here we present the crystallographic structuretween Cys168 and 182 and aromatic residues Phe227,
Trp215, and Trp60d. These residues constitute an allo- of thrombin in a slow conformation to 1.8 A˚ resolution,
which reveals the conformational basis of thrombin allo-steric switch, which is flipped directly through sodium
binding, resulting in the fast form with an open active stery and suggests a mechanism by which allosteric
activation is effected.site.
Introduction Results
The Asymmetric UnitHemostasis, the balance between bleeding and throm-
bosis, requires spatial and temporal control of blood Three molecules of human S195A thrombin constitute
the asymmetric unit and are denoted AB, CD, and EFclot formation. In large part this is achieved by tight
regulation of thrombin formation and clearance. Throm- to indicate the two chains that compose each monomer
bin is the final protease in the blood coagulation cascade (Table 1). Thrombin is normally a disulfide-linked two-
and is responsible for the cleavage of fibrinogen to fibrin, chain protein, with the light chain consisting of 36 resi-
which polymerizes to form a fibrin plug (or clot). The dues (Thr1h–Arg15) and the heavy chain consisting of
fibrin clot is crosslinked by the action of factor XIII after 259 residues (Ile16–Glu247). S195A thrombin is incapa-
proteolytic activation by thrombin. Thrombin also stimu- ble of self-cleavage at Arg1i-Thr1h, which is part of the
lates its own generation through the activation of factor maturation of -thrombin, and, therefore, all monomers
XI and cofactors V and VIII. Finally, thrombin activation have, approximately, an additional ten residues mod-
of platelets, mediated by cleavage of protease-activated eled N-terminal to the normal Thr1h terminus. The addi-
receptors (PARs) on the platelet surface, contributes to tion of these residues reveals the self-cleavage site to
platelet plug formation and the creation of procoagulant be a well-ordered, highly hydrogen-bonded  turn that
surfaces that support further activation of coagulation presents the P1 Arg side chain for rapid recognition
enzymes (for review see [1]). and hydrolysis by thrombin (data not shown; substrate
In addition to its ability to stimulate its own generation, numbering of Schechter and Berger [12]). In contrast to
thrombin also limits its own formation by activating the




Table 1. Data Processing, Refinement, and Model (1JOU)
Crystal
Space group P21
Cell dimensions (A˚) a  71.23, b  76.58, c  97.32,   106.64
Solvent content (%) 47
Data Processing Statistics
Wavelength (A˚) 1.244 (SRS Daresbury, Station 14.1)
Resolution (A˚) 24.7–1.8 1.99–1.82
Total reflections 427,741 47,987




Completeness (%) 98.8 96.2
Rmergea 0.080 0.464
Model







Average B factor (A˚2) 38.8
Refinement Statistics
25.0–1.80 A˚ 1.91–1.80 A˚
Reflections in working/free set 90,794/1,000 14,478/152
R factorb/Rfree (%) 22.2/24.5 35.1/33.8
Rms deviation of bonds (A˚)/angles () from ideality 0.006/1.3
Ramachandran plot, residues in
Most-favored region (%) 85.6
Additionally allowed region (%) 13.3
Generously allowed region (%) 1.1
Disallowed region (%) 0
a Rmerge  	hkl	i|Ihkl 
 Ihkl|/	hkliIhkl.
b R factor  	hkl||Fobs| 
 |Fcalc||/	hkl|Fobs|.
all previously published structures of thrombin, all of loops (T147, W147a, T147b, A147c, N147d, V147e,
G148). There is a small difference in backbone confor-the heavy chain can be built into density for the three
molecules in the asymmetric unit. mation of these loops when comparing AB and CD (C
rmsd of 0.36 and 1.95 A˚ for the 60-insertion and  loops,A stereo representation of the C traces of the three
thrombin molecules in the asymmetric unit is given in respectively), but a large difference is observed for the
active site-free monomer, EF (2.15 and 5.2 A˚). ConsistentFigure 1A, and their superposition is shown in Figure
1B. The molecules differ very little, with C rmsd’s of with earlier structures, the  loop is in different confor-
mations in the three molecules and is poorly defined,1.0 and 1.2 A˚ for the 304 and 303 equivalent residues
of AB and CD, respectively, when superimposed on EF. indicating a high degree of flexibility.
These structures were also nearly equivalent to pre-
viously published structures of thrombin, with rmsd’s of Active Site-Occupied Thrombin
Thrombin allostery is often discussed in terms of a0.85 A˚ for 1dm4 (S195A thrombin with fibrinopeptide
[13]) and 1.25 A˚ for 1hah (active site-free thrombin bound change in specificity from fibrinogen to protein C. The
most striking difference in the sequence of the cleavageto the hirugen peptide [14]). Figure 1A demonstrates how
the active sites of molecules AB and CD are occupied by sites on fibrinogen and on protein C is the substitution of
a hydrophobic residue to an Asp at position P3. Severalthe C terminus of chains C and E (Asp14l-Gly14m-Arg15
for P3–P1), respectively, and the active site of EF is attempts to crystallize thrombin bound to peptide frag-
ments containing a P3 Asp have been unsuccessful,unoccupied. The C terminus of chain A does not interact
with a crystallographically related molecule and can only since, in each case, the S1 pocket is not occupied by
the P1 Arg side chain, as required of a true Michaelisbe modeled up to residue Gly14m. The difference in the
conformations of the C termini of chains A, C, and E is complex [15]. As mentioned above, the active site-occu-
pied monomers, AB and CD, interact with the C terminusseen in Figure 1B. The superposition of AB and CD on
EF also shows that the main difference in backbone of the light chain of an adjacent monomer. The sequence
of the end of the light chain, Asp-Gly-Arg, resemblesconformation lies in the 60-insertion (L60, Y60a, P60b,
P60c, W60d, D60e, K60f, N60g, F60h, T60i, E61) and  the P3–P1 sequence of protein C and PAR-1, Asp-Pro-
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Figure 1. Stereo Representations of C
Traces of the Three Thrombin Molecules
Comprising the Asymmetric Unit
(A) Three thrombin monomers are found in
the crystallographic asymmetric unit; they are
denoted AB (green), CD (blue), and EF (red)
and are labeled to indicate regions of impor-
tance, with the light chains of each monomer
in a lighter shade. The active site of EF is
unoccupied, while those of AB and CD are
occupied by a peptide fragment from neigh-
boring molecules (labeled Arg15). In all three
monomers the active site is indicated by a
yellow ball in the position of the C of residue
195.
(B) C superposition of the thrombin mono-
mers, colored as above, indicates the regions
of structural divergence. The 60-insertion and
 loops are indicated.
Arg. Figure 2A shows how the C-terminal peptide of is unoccupied by protein atoms (Figure 2B). The confor-
chain C interacts with the active site of molecule AB. mation of the catalytic residues is not significantly al-
The binding of the P1 Arg is typical of all structures of tered, in spite of the S195A mutation and the lack of
thrombin with substrates and inhibitors containing an bound peptide. Reasonably large-scale movements of
Arg in the P1 position. P2 Gly is found mostly in sub- Ser195 and His57 have been reported in structures of
strates of factor Xa and is not typical of thrombin sub- thrombin where peptides were bound in a nonproductive
strates, being found only in antithrombin [1, 16]. In con- fashion [15], but structures of S195A thrombin bound
trast to P2 Pro, Gly adopts a trans conformation in to peptide [13] or protein substrates [17] and of bovine
response to the Asp at P3. Indeed, if P2 were changed thrombin with a free active site [18] show no significant
from Gly to Pro in the typical cis conformation, the car- movement of the catalytic residues (His57, Asp102, or
bonyl oxygen would occupy the same position as the Ser/Ala195). Thus, the catalytic triad does not move
OD2 of the P3 Asp in this structure. Although it is thus significantly in response to the S195A mutation or the
unlikely that this structure represents the Michaelis com- lack of active site-bound peptide or inhibitor.
plex of protein C or PAR-1 with thrombin, it does show The superposition of all atoms of the active site-free
how an Asp at P3 can be accommodated in an apolar monomer EF with AB, CD, 1dm4, and 1hah does, how-
pocket by folding back upon itself to form a strained ever, reveal a consistent conformational difference in
hydrogen bond (2.34 A˚) with its neighbor Gly14m. the position of residues in the 60-insertion loop and
Cys168, Cys182, Trp215, and Phe227 (Figure 2). The
effect of these small conformational changes is mani-Active Site-Free Thrombin
fested in gross changes in the surface properties in theIn contrast to monomers AB and CD, the third thrombin
molecule in the asymmetric unit has an active site that active site cleft. Figure 3 shows the surface contours of
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Figure 2. Stereo Diagram of Electron Density
Surrounding Active Site Residues
(A and B) Residues of the active sites of AB
(A) and EF (B) are shown with 2Fo
Fc electron
density contoured at 1 the rmsd of the map.
The active site of AB is occupied by the C
terminus of chain C (magenta), with residues
from P4 Ile to P1 Arg shown. Thrombin resi-
dues shown in yellow consist of (from top to
bottom) Trp60d, His57, Asp102 (behind sub-
strate), Ala195 (to the right of substrate),
Trp215 (immediately below substrate), Phe227,
and the disulfide bond between Cys168 and
182. Asp189 is shown in a salt bridge, with
the P1 Arg in the typical substrate-bound
conformation for reference. Thrombin resi-
dues of monomer EF (B) are as described for
AB, except that the active site is not occupied
by protein atoms. Instead, two acetate (ma-
genta rods) and two water (red balls)
molecules occupy the active site of EF. The
catalytic residues, including Asp189, are un-
altered, but significant conformational change
is observed in the aromatic residues and di-
sulfide bond shown in the figure.
(C) Soaking the crystals with heparin leads to
a reorganization of the residues in the alloste-
ric switch for monomer EF (yellow). Maps
were calculated with 1JOU after three rounds
of ten-step refinement in CNS (to 1.9 A˚). This
minimal refinement resulted in an R factor of
22.9 and an Rfree of 25.7, and the cell was
isomorphous (a 71.25, b 76.49, c 97.27,
and   106.71). The 2Fo 
 Fc map (blue) is
contoured at 1 the rmsd of the map, and
the Fo 
 Fc maps are contoured at 2.5
and 
2.5 the rmsd of the map (green and
red, respectively). Switch region residues for
monomer AB are included for comparison
(magenta) and correspond to the regions of
positive-difference density (green), sug-
gesting equilibrium between the two forms
within the crystal.
EF with those of two other thrombin structures, 1hah thrombin bound to the protein substrate heparin cofac-
tor II (HCII) [17]. The surface representations are coloredand 1jmo, chosen for comparison because 1hah has a
free active site and is bound via exosite I to the hirudin- according to hydrophobicity, with green indicating the
presence of hydrophobic side chains, in order to betterderived peptide hirugen and because 1jmo is S195A
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Figure 3. Stereo Representation of Surface
Contours of the Thrombin Active Site Pocket
Thrombin is shown in the classical “Bode”
orientation, with the active site facing and the
substrate binding from left to right for N- to
C-terminal. The 60-insertion loop is located
above the substrate. The surface contours
are colored according to hydrophobicity, with
green indicating the presence of an exposed
hydrophobic side chain. The substrate bind-
ing site is indicated in (A) by the inclusion of
the reactive center loop P4–P4 of HCII in
complex with S195A thrombin (1jmo), and the
peptide is removed for comparison in (B). Al-
losterically activated thrombin (C) is repre-
sented by the active site-free, hirugen-bound
form (1hah) and is nearly identical to that of
the substrate-bound form in (B). In contrast,
the active site cleft of molecule EF (D) is sig-
nificantly different, primarily because of the
position of side chains Trp60d and Trp215
(Figure 2). Comparing substrate-bound throm-
bin in (A) to the substrate-free form in (D) re-
veals a complete occlusion of the P2 and aryl
binding pocket in the active site-free mono-




illustrate important changes in the conformation of the sic fluorescence enhancement upon cofactor binding
and thus must undergo a significant change in environ-active site cleft. The strength of thrombin subsite inter-
actions with substrates is overwhelmingly provided by ment in the transition from the slow to the fast form.
The molecular picture that emerges from these biochemi-hydrophobic interactions and the exclusion of water [19–
22]. Such an interaction is shown in panel A to illustrate cal studies was lucidly described by Wells and Di Cera:
the extent of subsite interactions from P4 (Phe) to P4
The conformational change slow → fast must be
(Val) and how the active site cleft accommodates a sub- such to drastically enhance the rate of substrate
strate. It is striking that the active site cleft of hirugen- binding to the enzyme by widening the access to
bound, active site-free thrombin, 1hah, is nearly identical the catalytic pocket. Recent structural findings
to the substrate-bound form, 1jmo (compare panel C have pointed out the peculiar position of three
tryptophan residues in the B chain, Trp60d,with panel B). This is in contrast to the shape of the
Trp215, and Trp148, that shape the access to theactive site cleft of EF (panel D), which conforms in neither
catalytic pocket (Bode et al. 1992). It is tempting toshape nor surface properties. When the P4–P4 residues
speculate that the slow → fast transition might beof HCII are placed in the active site of EF, three residues
linked to the displacement of one or more of thesemake significant steric clashes and overlaps: P4 Phe
residues with a resulting widening of the access to
clashes with Trp215, P2 Pro overlaps with Trp60d, and
the catalytic pocket. The displacement would
P4 Val overlaps with Asp60e. Thus, the active site cleft be responsible for the change in intrinsic
of EF is unable to bind substrates without significant fluorescence measured experimentally, as well as for
conformational rearrangement of the 60-insertion loop the substantial increase in k1*. . . . Access to the
and Trp215 and can be described as “closed” relative catalytic pocket opens up when Na is bound and
remains in a wide open configuration during allto other thrombin structures.
steps of catalysis. As a result of this, substrate
binding occurs on a faster time scale, and so do
substrate dissociation and deacylation, which involveDiscussion
escape from the active site to the solution. In the
slow conformation, all these steps areThrombin was first recognized as an allosteric enzyme
significantly slowed down with a resulting decrease
in 1980 by Orthner and Kosow, who demonstrated a
in the catalytic efficiency of the enzyme. [11]
change in both kcat and Km in response to sodium and
potassium ion binding [23]. This was the first of many So how does the structure of the active site-free form
presented here, EF, compare with the molecular picturepapers published on the allosteric properties of throm-
bin in the last 22 years. In this time a consistent picture painted above? As illustrated in Figure 3, the conforma-
tion of the active site pocket of EF is constrained inof the thrombin conformational change responsible for
its allosteric activation has emerged, in spite of the ab- comparison with structures where cofactor or substrate
is bound. In fact, the substrate binding pocket does notsence of a crystallographic structure of the kinetically
slow form. Therefore, any new thrombin structure claim- exist in EF because of the occlusion of the S2 and aryl
(S3 and S4) binding pockets. Thrombin specificity ising to represent the slow form must run the gamut of
biochemical and biophysical criteria accumulated over precisely defined by residues P2–P4, when P1 is held
constant as Arg and the active site pocket of EF showntwo decades.
Several studies have noted a change in environment in Figure 3 would be incapable of productively binding
substrates. The residues responsible for the closed con-of aromatic side chains. Differential UV absorbance
spectra indicated a shift in environment of tyrosines formation of the active site cleft of EF are Trp60d and
Trp215. Figure 2 illustrates how the side chain orienta-and/or tryptophans from a polar to an apolar environ-
ment [23, 24]. This was supported by the observation tion of these residues in EF precludes substrate binding.
Crucially, it is these residues that have been singled outof an increase in the fluorescence quantum yield of
thrombin upon Na or other cofactor binding [11, 25]. by mutagenesis to be critical for allosteric activation,
with substitutions of either residue leading to a signifi-On the basis of kinetic, absorbance, and fluorescence
studies with Na and exosite binding cofactors, it was cant loss in cofactor binding affinity and a decoupling
of cofactor binding and activation. As stated in the paperconcluded that the conformational change and kinetic
pathway between the slow and fast forms was con- by Guinto and Di Cera [28], “Mutation of W60d changes,
both quantitatively and qualitatively, the allosteric com-served for all cofactors [26]. Careful kinetic studies have
demonstrated that the conformational change involves munication between the active site and the fibrinogen
recognition site.” On the basis of the properties of thethe widening of the active site cleft [11]. It is the widening
of the cleft that is responsible for the improved Km and mutants, they proposed “that W60d occupies different
positions in the slow and fast forms.” Trp215 also mustkcat through an increase in the rates of substrate associa-
tion and product dissociation. Studies on -thrombin change conformation upon activation, as its movement
from a solvent-exposed to a buried environment ac-and subsequent mutagenic studies proved conclusively
that residues on the  loop were not involved [11, 27] counts for all of the intrinsic fluorescence enhancement
thrombin experiences upon cofactor binding [29]. In alland that critical residues included Trp60d and Trp215
[27–29]. Trp60d and Trp215 are both located over 10 A˚ previous structures of thrombin, Trp215 is in an identical,
buried position. In the structure of EF, the tryptophanaway from the Na binding site, yet substitutions at
these positions result in a significant loss of Na binding side chain is partially solvent exposed, with an accessi-
ble surface area of 36.4 A˚2, as opposed to 10.6 A˚2 foraffinity and trap thrombin in the slow form. In addition,
Trp215 was found to be solely responsible for the intrin- molecule AB (calculated with the program Surface, with
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a probe radius of 1.4 A˚.). Compelling evidence that bury- tacts can tip the balance. It has been demonstrated that
Na binding by thrombin is a complex process involvinging of Trp215 is a critical part of the allosteric mechanism
and directly linked to Na binding is provided by the several conformations in equilibrium and that there is a
rapid equilibrium between the Na-bound slow and fastW215F and W215Y mutations. W215F is nearly identical
to the wild-type in all measures except fluorescence forms [26]. It could thus be argued that the conformation
of monomer EF is an artifact of crystallization. However,enhancement, which is abolished, whereas W215Y has
a 3-fold reduction in affinity for Na [29]. The difference although crystallization has stabilized the slow form suf-
ficiently for unequivocal density to be obtained for thein affinity amounts to 1 kcal/mol in free energy and corre-
sponds well with the energy required to bury a hydroxyl residues involved in thrombin allostery (Figure 2), the
crystal contacts are in themselves not sufficient. Thesegroup in a hydrophobic environment when no hydrogen
bonding partner is available [30], as would be the case crystals were grown in conditions containing enough
glycerol to provide cryoprotection and were thus takenfor the hydroxyl group of Tyr when superimposed on
Trp215 in the fast conformation. directly from the drop in which they were grown and flash-
cooled to 100 K. Another crystal was soaked for severalThus, on the basis of the predictions from years of
biochemical studies, it is possible to conclude that the hours in a solution containing a heparin analog under
slightly altered conditions. The resulting structure wasactive site-free form of thrombin in our crystal is the
elusive slow form. It is important to note that, in spite nearly identical, but, in molecule EF, the residues involved
in the allosteric mechanism (Cys168, Cys182, Trp215,of efforts to obtain crystals of the slow form through
either soaking out the Na after crystallization or crystal- Phe227, and Trp60d) had become disordered through the
sampling of multiple conformations (probably just two;lization in the absence of Na, the constraints imposed
upon thrombin within the crystal resulted in thrombin Figure 2C). Such an equilibrium between a sodium-bound
slow conformation and a sodium-bound fast conformationwith its active site pocket adopting the fast conformation
[31, 32]. The recently published structure of thrombin has been postulated on the basis of stopped-flow studies
[26], and this equilibrium exists even within the constraintscrystallized in the absence of sodium (1MH0; 2.8 A˚) pos-
sesses an active site cleft in the open conformation, of the thrombin crystal described here.
The conformation of EF not only provides a structuraland the reported small changes in the position of the
catalytic side chains are not unique to the sodium- explanation for the biochemical properties of the slow
form of thrombin, but it also reveals the link betweenfree form (see Supplemental Figure S1 at http://www.
structure.org/cgi/content/full/11/4/469/DC1). Indeed, the Na binding site and the active site pocket some
15 A˚ distant. Figure 2 illustrates how the local structuresimilar side chain movements have been observed in
several structures where Arg is not bound in the S1 of Trp60d is conformationally linked through Trp215 and
Phe227 to the disulfide bond between Cys168 andpocket (1hah, 1nrn, 1nro, 1nrp, 1nrq, 1jmj, and EF), indi-
cating that the catalytic residues are inherently flexible Cys182. These side chains change their orientations in
concert and comprise the allosteric switch between thein the absence of bound substrate or inhibitor (see Sup-
plemental Figure S1C). This flexibility is also evident in slow and fast forms. The unique conformation of the
allosteric switch of EF is demonstrated by the superpo-the two sodium-free molecules that occupy the asym-
metric unit of 1MH0 (in spite of the tight NCS restraints), sition of all deposited thrombin structures (human and
bovine) of resolution better than 3 A˚ (see Supplementalwith one Ser195 O–His57 N distance of 3.6 A˚ and
another of 3.3 A˚ (see Supplemental Figure S1B). Thus, Figure S2 at http://www.structure.org/cgi/content/full/
11/4/469/DC1). Although there is a reported movementeven when, in solution, the slow form is predominant,
the fast form is sampled sufficiently often for it to prefer- of the 60-insertion loop in a structure of an active site-
free form of bovine thrombin [33], the side chains ofentially crystallize out. In this manner the crystal pro-
vides a thermodynamic sink. There are many examples Tyr60a and Trp60d superimpose on those of other fast
forms, as do all other residues in the allosteric switchin the literature of minor solution conformers being
trapped through crystallization. The affinity of thrombin region. The structures of thrombin bound to protein in-
hibitors ecotin [34] and BPTI [35] appear to be excep-for Na is indeed very low, making it even more likely.
It is easy to see how crystal contacts could satisfy this tions to the structural conservation, since, in both struc-
tures, the 60-insertion loop is significantly reoriented toenergetic difference and explains why, in spite of great
effort, the slow form has remained elusive. accommodate the relatively large inhibitor. However, the
positions of all other residues of the allosteric switchUnder the crystallization conditions used to obtain
our crystals (85 mM NaCl), we would expect the Na- are conserved. In addition to the structural conservation
of these residues, the allosteric switch residues (Trp60d,bound form to predominate by a ratio of between 4:1
and 5:1. Indeed, all three thrombin monomers in the Cys168, Cys182, Trp215, and Phe227) are all perfectly
conserved for all known and putative thrombin se-asymmetric unit contain an octahedrally coordinated
sodium ion. The same reasons that led to the crystalliza- quences, from the African crocodile to man (data not
shown). Thus, we conclude that the active site-free mo-tion of the fast form in the absence of Na apply here—
crystal contacts allow for a minor solution conformer to nomer, EF, represents the first crystallographic structure
of thrombin in its slow conformation, where its activebe preferentially withdrawn from the solution into the
thermodynamic well of the crystal lattice. The small en- site pocket is closed because of the position of the side
chains of Trp60d and Trp215. In response to cofactor,ergetic difference between the two forms imposes the
absolute requirement of luck to obtain the less stable substrate, or Na binding, the position of these trypto-
phans is altered in concert with the flipping of the disul-conformer, especially when substrate, inhibitor, exosite
I and II cofactors, monovalent cations, and crystal con- fide bond between Cys168 and 182 and the rotation of
Structure
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Figure 4. Stereo Depiction of the Sodium
Binding Site Reveals Both through Bond and
through Space Contacts with the Residues
of the Allosteric Switch
The effect of conversion from the slow (B) to
the fast (A) form is the stacking of aromatic
residues Trp215 and Phe227 with the disul-
fide bond between Cys168 and 182. The im-
proved packing of these residues withdraws
Trp215 from Trp60d (top), which then adjusts
to find its new thermodynamic minimum,
thereby opening the active site pocket and
allowing the productive binding of sub-
strates. This equilibrium between the two
forms is altered because of the binding of a
single sodium ion (purple). Na is coordinated
by the main chain carbonyl oxygens of
Arg221a and Lys224 and four water mole-
cules. Tyr225 is one residue away from
Lys224 and two residues away from Phe227,
so it is connected through bonds to the allo-
steric switch. It is also connected through
space, making van der Waals contacts with
Cys182 in the fast, but not the slow, confor-
mation.
the benzyl group of Phe227. A video representation of binding from activation [27, 36, 37]. The effect of stabiliz-
ing the loop containing Tyr225 through Na binding maythe conformational changes in the switch region and in
the surface properties of the active site cleft is available be sensed directly through bonds by allosteric switch
residue Phe227 or through space with the Tyr225 sideas Supplemental Data at http://www.structure.org/cgi/
content/full/11/4/469/DC1. chain only 3.6 A˚ away from the Cys168-182 disulphide
bond in the fast form and 4.4 A˚ away in the slow formHow then does Na binding flip the allosteric switch?
Na is coordinated octahedrally by the carbonyl oxy- (Figure 4). Indeed, the distance between the sulfur atom
of Cys182 and the C of Tyr225 of 3.6 A˚ places themgens of Arg221a and Lys224 and by four water mole-
cules [31]. Mutation of residues flanking the binding in van der Waals contact in the fast form, whereas these
atoms are not in contact in the slow form. The directsite (Asp221, Asp222, and Tyr225) significantly reduce
affinity for Na, and, in particular, Y225P decouples Na link between the Na binding region and the active site
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through the allosteric switch described here argues of an altered equilibrium position. The role of Na bind-
ing to hemostasis is further called into question by thestrongly against the previous hypothesis of a water
channel-mediated conformational change [28]. tightly controlled levels of Na in blood (between 136
and 143 mM) and the fact that deviations in Na concen-Finally, can the mechanism of sodium allostery be
generalized for the other thrombin cofactors, in particu- tration have never been correlated with thrombosis or
bleeding. The reported “anticoagulant” effect of throm-lar, the hirudin peptide (hirugen), heparin, and TM? Con-
sidering the small energies involved, anything that binds bin mutant W215A/E217A [41] is most likely due to an
overall reduction of enzymatic activity [29], which, forto thrombin is likely to alter the position of the equilib-
rium between the slow and fast forms, in particular, protein C cleavage, is partially recovered through the
binding of endogenous TM.anything that binds in the active site cleft or near the
allosteric switch region will favor the fast form. Hirugen
Experimental Proceduresdoes not interact with the allosteric switch but binds to
the extended fibrinogen binding region of exosite I and
Recombinant human S195A thrombin was prepared as describedforms significant contacts on the P side of the active previously [42]. Thrombin from this preparation is inactive because
site cleft, which is sufficient to explain the stabilization of the active site substitution and, therefore, cannot self-process.
of the fast form. Although no structure of heparin bound Crystals were obtained from the original Hampton Cryo Screen #9
(170 mM ammonium acetate, 85 mM sodium citrate [pH 5.6], 25.5%to thrombin has been published, mutagenic studies have
PEG 4000, and 15% glycerol [final pH 7.0]) after7 months at roomidentified several residues involved in heparin binding
temperature. Although it has been suggested that the S195A form[1, 38–40]. In addition, a surface electrostatic represen-
maintains some activity [13], no evidence of autolysis was seen,tation of exosite II reveals a basic channel composed of even after such a long incubation. This discrepancy may be due to
Lys235, Arg233, Arg165, and Lys169 (see Supplemental the removal of trace proteolytic contaminants from our preparation.
Figure S3 at http://www.structure.org/cgi/content/full/ Data were collected from a single crystal cooled to 100 K in
vapor nitrogen at the SRS (Daresbury, UK; station 14.1) on an ADSC11/4/469/DC1), which may also be involved in heparin
Quantum 4 image plate. The data were processed with MOSFLM,binding and would provide a direct link to the disulfide
SCALA, and Truncate [43] and were of reasonable quality to a resolu-bond at the base of the switch (Cys168). In contrast,
tion limit of 1.8 A˚ (Table 1). The structure of S195A thrombin wasthe EGF-like domains 4–6 of TM do not bind near the solved by molecular replacement (MolRep) [44], with the highest
allosteric switch in the crystallographic structure (1dx5). resolution structure (1.6 A˚) of thrombin at that time (1AHT) as the
It is possible that there are further interactions in exosite search model. Three molecules were placed in the asymmetric unit.
The model was subjected to rigid-body refinement and coordinateI and in the substrate binding pocket with untruncated
refinement with simulated annealing with CNS [45, 46]. IterativeTM, which are not represented in the structure, or that
rounds of rebuilding in XtalView [47] and refinement with CNS (with-TM binding indirectly alters the equilibrium position be-
out NCS restraints) resulted in an R factor and Rfree of 22.2 and 24.5,tween the slow and fast forms. In either case, it appears respectively (Table 1). Figures were made with XtalView, Molscript
that the effect of TM binding on thrombin specificity is [48], Bobscript [49], Raster3D [50], and Spock. Chymotrypsin num-
significantly the result of steric interference with fibrino- bering is used throughout.
gen and direct interactions with protein C for improved
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